Jean‐Jacques Diaz

This study identifies CYCLON as a nucleolar protein that regulates cancer cell fitness by controlling ribosome biogenesis and nucleolar structure across multiple tumor types.

This study identifies eL21 as an externalized ribosomal protein in triple negative breast cancer cells and shows anti-eL21 antibodies induce anti-proliferative effects.

This study identifies ribosome biogenesis as a therapeutic vulnerability in TNBC, showing that inhibiting rRNA maturation via Fibrillarin or RNA Pol I reduces tumor growth without significant cell death.

This study investigates ribosome biogenesis as a therapeutic target in neuroblastoma, showing that inhibiting RNA polymerase I reduces cell proliferation and induces apoptosis.

The paper shows 5-FU induces translational reprogramming in colorectal cancer cells, enhancing drug tolerance through pro-tumoral gene expression and IL-8 overexpression.

The paper identifies a shared neoepitope from non-canonical c-MYC translation in cancer cells that activates T cells to kill tumors without harming normal cells.

This study identifies RSL24D1 as a key regulator of ribosome biogenesis and pluripotency in mouse embryonic stem cells, showing its role in maintaining self-renewal and suppressing differentiation.

This paper shows DHX30 coordinates cytoplasmic and mitochondrial translation, affecting cancer cell survival and prognosis through a 15-gene signature.

This study shows that Fanconi anemia proteins are essential for maintaining nucleolar homeostasis, with loss-of-function leading to nucleolar DNA damage, rDNA rearrangements, and impaired ribosome biogenesis.